Allogene Therapeutics, Inc. (ALLO) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Truist Securities Reiterates Buy Rating on Allogene (ALLO)
May 14, 2024 8:03 AM EDTTruist Securities analyst Asthika Goonewardene reiterated a Buy rating and $17.00 price target on Allogene (NASDAQ: ALLO)
The analyst comments "Two key positives from 1Q24 should make the stock more attractive, in our view: (1) Gaining EU/UK rights to lead asset... More
